October 2013

About ISEH

The mission of ISEH is to promote the scientific knowledge and clinical application of basic hematology, immunology, stem cell research, cell and gene therapy, and all related aspects through research, publications, discussion, support of young investigators and organization of scientific meetings.

In this Issue

Annual Meeting News

News from the Field

Member Profile

Society News

Don't Miss These Meetings

Experimental Hematology


Members' Corner

Interested in reaching your target audience? For only $500 you can place a banner advertisement in ISEH Connections Newsletter. Contact ISEH at info@iseh.org

President’s Message: Experimental Hematology is the core of ISEH

It is a special honor and a privilege to serve as President of ISEH. I am committed to using this opportunity to further strengthen our Society so it can continue to flourish for years to come. One of my main goals for this year is to promote Experimental Hematology (ExpHem), the ISEH's official journal, increasing submissions, and improving the impact factor. Experimental Hematology has been the Society's flagship journal for over 40 years and is a main source of income that we use to subsidize the Annual Meeting, particularly supporting the many fellowships we offer for trainees. It is in all the members' interests to keep the journal healthy and vibrant.

Keith Humphries became the Editor in Chief in 2011, and he is supported by a strong editorial team. They introduced several attractive features and have been working on reducing the time to publication. ExpHem has an average time to first decision of 3.5 weeks; articles are published online and are fully citable within 5 days of acceptance. The "Fast Track” option allows you to provide reviews you have received from another journal alongside your submission. Depending on the situation, these can be used by the editorial team to make rapid decisions – sometimes in less than one week. In addition, there is a new "brief communication” option for short reports of importance that may not be fully developed stories. See the author guide for more details. For Society members there is no submission fee or page fee for articles published. ExpHem is widely read, with over 280,000 downloads articles each year; over 25% downloads are by US readers. With ExpHem you get an extremely knowledgeable and dedicated editorial team and an audience of readers who will appreciate the value of your work.

It is important that we all do our part to support Experimental Hematology. Please submit your strong papers to the journal, and see whether there are appropriate recent articles in Experimental Hematology to cite in your own research manuscripts.

Best wishes,

Margaret (Peggy) Goodell
ISEH President

Annual Meeting News

Report of the 42nd annual ISEH conference - A new investigator perspective

Contributed by Courteney Lai Graduate Student, BC Cancer Agency, Vancouver, BC and Dr. Joanna Wegrzyn, postdoctoral fellow BC Cancer Agency, Vancouver, BC.

The Art of Science in Vienna

Vienna, the capital of Austria, is known as a cultural epicenter of Europe; a city which seamlessly weaves its historical, artistic, and scientific past with the modern world of technology and urban life. Vienna is well known in many cultural circles: as the City of Music, due to its rich legacy as a leading music centre; the City of Dreams, as home to the first psycho-analyst, Sigmund Freud, and for its rich architectural history that embraces its Roman roots, Gothic and Baroque influences, and modern architecture. Read more on website

News From the Field

News roundup: October 2013

A collection of industry, policy, government and other hot news from the field of hematology and stem cell.

OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)

Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation

First patient treated in groundbreaking stem cell therapy trial for heart attack

Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants

Celator® pharmaceuticals announces start of clinical study in patients with untreated myelodysplastic syndrome (MDS) or acute myeloid leukemia at high risk of treatment-related mortality

Gamida Cell Announces the Successful Transplantation of the First Patient in The Company’s Phase I/II Study of NiCord® in a Single Cord Configuration

Volasertib* receives FDA Breakthrough Therapy designation for treatment of patients with acute myeloid leukaemia

Factor Bioscience Granted First U.S. Patent for RNA‐Based Reprogramming Technology

Member Profile

Meet Karin Klauke - New Investigator Award Winner 2013

Karin Klauke is a PhD candidate working in the Laboratory of Ageing Biology and Stem Cells at the European Research Institute for the Biology of Ageing, a part of the University Medical Centre Groningen in the Netherlands. She has been in the stem cell research field for 6 years, and an ISEH member for 5 years. She first joined ISEH when her supervisor Gerald de Haan suggested that she submit an abstract about her research to present at the ISEH meeting in Athens, Greece. Klauke was selected to make a presentation at the meeting, her first outside her laboratory.
Read more on website

Society News

It's ISEH membership renewal season! Renew now using new login information

ISEH Membership renewal season is upon us once again, and it’s never been easier to renew you membership online.

Your ISEH.org login information has changed!

New Login: your email address, example: ISEHmember@yourfacility.com
New Password*: welcome1

Once you have logged in, pay your dues by clicking on "Securely renew your membership." If you are not automatically directed to this page upon your login, click here to access the renewal page.

new for 2014, Active members can renew for two-years and then cross "renew ISEH membership” off your to-do list for next year!

Do you know 5+ scientists who should be members of ISEH and have been waiting for the right moment? The time has come, ISEH is offering group membership rates for groups of five or more new members from the same facility, email info@iseh.org for more details.

Frenette and Scadden's stem cell niche webinar recap

Contributed by Eugenia Flores-Figueroa, ISEH New Investigator Committee

Technology is changing the way we do and share science. As an international society, webinars are a useful tool to keep our members informed and connected throughout the year.

On September 23rd, the New Investigator Committee hosted the second ISEH webinar, featuring a discussion between two of our prominent members and leaders in the field of the hematopoietic stem cell niche. David Scadden and Paul Frenette gave an overview of the field and shared their latest results. With Andreas Trumpp as the moderator, the webinar/debate flowed smoothly and was interesting from beginning to end. Read more on website

Don't Miss These Meetings

Keystone and ISCT highlight early 2014 offerings

Keystone Symposia: Stem Cells and Cancer
February 2-7, 2014-Banff, Canada

20th International Society for Cellular Therapy (ISCT) Annual Meeting 2014
April 23-26, 2014-Paris, France
Read more on website

Experimental Hematology

Experimental Hematology offers fast publication time

Experimental Hematology offers one of the fastest publication times in the field
Read more on website

Inside the September and October 2013 issues

Take a quick tour of the March and April issues and get a feel for the publication's cutting-edge scientific content. Read the full issues online.

In this Issue – September 2013

Cohesin: a master regulator of hematopoietic transcriptional programs
Panigrahi et al., pages 967–973.

Tissue-specific T-regs: potential prognostic markers for acute graft-versus-host disease
Engelhardt et al., pages 974–982.

The unexpected role of Pbx3 in leukemic transformation
Novak et al., pages 1016–1027.

In this Issue – October 2013

Burst-forming unit–erythroid assays in bone marrow failure
DeZern et al., pages 808–816.

Ciclopirox inhibition of mTOR provides a potential new approach to targeting AML
Sen et al., pages 799–807.

A chimeric lentiviral vector for both human and non-human primates hematopoietic repopulating cells
Uchida et al., pages 779–788.

The role of the microenvironment during fetal hematopoieisis
Cao et al.,pages 761–768.

NEW! Experimental Hematology now accepts brief communications

Experimental Hematology welcomes articles that can be reported in a shorter format. Brief communications are intended to allow publication of highly significant findings reported concisely, and not of incomplete or preliminary data. As with regular submissions, brief communications are expected to provide mechanistic insights, elucidate novel disease biology or approaches to therapy. Click here to learn more.

Regular and fast-track submissions are encouraged

The publishing team seeks manuscripts, reviews, perspectives and letters to the editor describing basic in vitro and in vivo research centered on normal and malignant hematopoiesis, as well as non-malignant hematologic diseases. Read more on website


Editors Pick: Worldwide postdoc and career opportunities

Postdoctoral Fellow (San Francisco, California)

Faculty Positions-Stem Cell Biology & Developmental Biology (New York, New York)

Director/Senior Director Clinical Research - Hematology/Oncology (Waltham, MA)

Postdoctoral position in RNA & Stem cell biology (Lyon, France)

Postdoctoral Research Fellow / Research Officer - Stem Cells (Singapore)

Associate Director Medical Affairs, Scientific Lead, Hematology / Oncology Job (Summit, New Jersey)

Members' Corner

ISEH applauds members' outstanding accomplishments

Congratulations to:

Dr. Elaine Dzierzak from the Erasmus Stem Cell Institute of the Erasmus University Medical Center in Rotterdam (and University of Edinburgh beginning 1 October 2013) has been awarded an Advanced Grant of the European Research Council (ERC). This award will support Dzierzak’s research on hematopoietic stem cells. Her lab has taken a developmental approach to provide insight into the growth and transcription factors essential for the embryonic development of these important adult stem cells. Dzierzak will use this knowledge within the ERC-project to attempt the de novo generation of hematopoietic stem cells in culture by the transdifferentiation of patient somatic cells. This research will contribute significantly to the progression of basic scientific insights towards clinical application.

ISEH is very proud of our members' accomplishments. Please send any news that you would like to share with your colleagues to exphem@iseh.org.